Clinical Trials Directory

Trials / Conditions / Transformed Lymphoma

Transformed Lymphoma

14 registered clinical trials studyying Transformed Lymphoma — 6 currently recruiting.

StatusTrialSponsorPhase
RecruitingPOLA-R-CHP in the First-line Treatment of Transformed DLBCL
NCT06743945
Fudan UniversityPhase 2
RecruitingAcalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
NCT05256641
Jonsson Comprehensive Cancer CenterPhase 1 / Phase 2
RecruitingMosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
NCT05412290
Washington University School of MedicinePhase 1
RecruitingLocal Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem
NCT05281809
John ListerPhase 2
RecruitingDALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489
Miltenyi Biomedicine GmbHPhase 2
UnknownTislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
NCT04796857
Huiqiang HuangPhase 1 / Phase 2
RecruitingAnti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
NCT04545762
C. Babis AndreadisPhase 1
UnknownCamrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
NCT04476459
Huiqiang HuangPhase 1 / Phase 2
UnknownToripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
NCT04058470
Huiqiang HuangPhase 1 / Phase 2
CompletedAxicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
NCT04319237
H. Lee Moffitt Cancer Center and Research Institute—
UnknownDLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
NCT03837873
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2
CompletedExploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell
NCT04067414
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
Completed1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
NCT03133221
University of Maryland, BaltimorePhase 2
CompletedRituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
NCT00225212
Stanford UniversityPhase 2